Date — Jan 31
3:30 pm - 7:30 pm
The Nippon Club
Sign up now for New York Pharma Forum’s January Program
Topic 1 : Health Care Reform and Drug Pricing in Japan
Takuno Yoshida, First Secretary for Health and Welfare, Embassy of Japan to the United States
Topic 2: Trends in Oncology
Oncology is a rapidly evolving marketplace with many biopharma companies seeking to develop and commercialize new breakthroughs in science and technology. In recent years, novel immuno-oncology therapeutics have unlocked new levels of durable efficacy and have reshaped therapeutic paradigms and markets landscapes accordingly. Additionally, new modalities such as cell and gene therapies are being applied to the oncology field, creating further complexities for biopharma players to navigate to remain competitive in the space. Peter Lang and Joosung Kim will share from their experience helping diverse biopharma stakeholders navigate these and other trends in the oncology space.
*Click names for bios
Peter Lang, Managing Director, Life Sciences, Navigant
Mr. Lang has over 20 years of consulting and industry experience working with pharmaceutical and medical device clients. He has deep expertise in the areas of strategy development and strategic brand planning, product launch, marketing, business development, new product evaluation and post-merger integration. Peter is a published author and has frequently presented on the topic of strategic brand planning at industry conferences. Prior to joining Leerink Swann Consulting (and now Navigant Consulting), Peter was a Principal at Archstone Consulting and a Director of Channel Sales at Masimo. Peter was also a Clinical Trials Manager at Vital Insite and a Software Engineer at Siemens Medical Systems. Mr. Lang received a Master of Applied Science degree in Biomedical Engineering from the University of Toronto, and a Bachelor of Applied Science degree in Electrical Engineering, also from the University of Toronto.
Joosung Kim, PharmD, Associate Director, Life Sciences, Navigant
Dr. Kim leads the Oncology Working Group at Navigant, which focuses on competitive analysis, opportunity assessments, scientific landscape assessments, and business development strategy in the oncology space. Prior to joining Navigant, Joosung held an industry-based fellowship with the Institute for Pharmaceutical Industry Fellowships in partnership with Bayer. In this role, Joosung served as an analyst in the Global Business Development & Licensing group, and led search and evaluation exercises as well as due diligence initiatives across oncology, cardiopulmonary, women’s health, and neurology therapeutic areas. Joosung received a PharmD with honors from the Ernest Mario School of Pharmacy at Rutgers University, with a focus on clinical pharmacology and pharmacy therapeutics.